Faron presents BEXMAB data at ASH Annual Meeting
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Faron Pharmaceuticals Oy (FARON)
"Faron Pharmaceuticals Oy stock price live, this page displays LON FARN stock exchange data. View the FARN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Faron Pharmaceuticals Oy real time stock price chart below.
What Is the Faron Pharmaceuticals Oy Stock Price Today?
The Faron Pharmaceuticals Oy stock price today is 2.17.
What Is the Stock Symbol for Faron Pharmaceuticals Oy?
The stock symbol for Faron Pharmaceuticals Oy is ""FARN.""
What Stock Exchange Does Faron Pharmaceuticals Oy Trade On?
Faron Pharmaceuticals Oy is listed and trades on the London stock exchange.
Is Faron Pharmaceuticals Oy a Good Stock to Buy?
Determining whether Faron Pharmaceuticals Oy—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the FARN quote. (ISIN: FI4000153309)"
What Is the Faron Pharmaceuticals Oy Stock Price Today?
The Faron Pharmaceuticals Oy stock price today is 2.17.
What Is the Stock Symbol for Faron Pharmaceuticals Oy?
The stock symbol for Faron Pharmaceuticals Oy is ""FARN.""
What Stock Exchange Does Faron Pharmaceuticals Oy Trade On?
Faron Pharmaceuticals Oy is listed and trades on the London stock exchange.
Is Faron Pharmaceuticals Oy a Good Stock to Buy?
Determining whether Faron Pharmaceuticals Oy—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the FARN quote. (ISIN: FI4000153309)"
2.17
-0.04(-1.81%)
Closed
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.15
2.21
52 wk Range
1.05
2.97
FARON Scorecard
Full Analysis
Suffers from weak gross profit margins
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.152.21
52 wk Range
1.052.97
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
FARON Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts do not anticipate the company will be profitable this year
- Faron's bexmarilimab granted UK innovation passport
- Investing.com
- Faron presents BEXMAB data at ASH Annual Meeting
- Investing.com
- Faron's bexmarilimab granted UK innovation passport
- Investing.com
Faron Pharmaceuticals Oy Company Profile
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company’s lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. The company is also developing bexmarilimab, which is in phase 2 clinical trial for indications of solid tumors; and in phase 1 clinical trial for indications of acute myeloid leukemia and myelodysplastic syndromes. In addition, it develops interferon beta-1a to prevent toxicities from CAR-T therapy in phase 2 clinical trial; and AOC3 inhibitor, which is in preclinical studies for indications of chemotherapy-induced neutropenia. Further, it develops Haematokine, an investigational AOC3 protein inhibitor that is used for regenerative medicines in hematological malignancies, as well as chemotherapy induced suppression of the bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.
Compare FARON to Peers and Sector
Metrics to compare | FARON | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipFARONPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.5x | −2.3x | −0.6x | |
PEG Ratio | −1.30 | 0.00 | 0.00 | |
Price/Book | 173.0x | 1.7x | 2.6x | |
Price / LTM Sales | - | 11.6x | 3.1x | |
Upside (Analyst Target) | 27.9% | 331.0% | 50.2% | |
Fair Value Upside | Unlock | 6.4% | 7.5% | Unlock |
Earnings
Latest Release
Nov 27, 2024
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
FAQ
What Is the Faron Pharmaceuticals Oy (FARON) Stock Price Today?
The Faron Pharmaceuticals Oy stock price today is 2.17
What Stock Exchange Does Faron Pharmaceuticals Oy Trade On?
Faron Pharmaceuticals Oy is listed and trades on the Helsinki stock exchange.
What Is the Stock Symbol for Faron Pharmaceuticals Oy?
The stock symbol for Faron Pharmaceuticals Oy is "FARON."
What Is the Faron Pharmaceuticals Oy Market Cap?
As of today, Faron Pharmaceuticals Oy market cap is 239.42M.
What is Faron Pharmaceuticals Oy Earnings Per Share?
The Faron Pharmaceuticals Oy EPS is -0.46.
What Is the Next Faron Pharmaceuticals Oy Earnings Date?
Faron Pharmaceuticals Oy will release its next earnings report on 26 Feb 2025.
From a Technical Analysis Perspective, Is FARON a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.